分次放疗联合立体定向放射外科推量控制2级脑膜瘤大体病灶
单中心回顾性队列纳入2009—2023年接受手术切除、分次放疗联合立体定向放射外科推量的14例2级脑膜瘤患者,推量靶区3年局部控制率100%,18个月无进展生存率92.3%、总生存率100%;3例(23%)出现≥3级不良事件,包括放射性坏死、癫痫发作和认知下降。
要点
- 14例2级脑膜瘤接受分次放疗54 Gy(中位)联合立体定向放射外科推量7.5 Gy(中位)。
- 可随访13例中位随访34个月,3例(23%)治疗失败,均未发生在推量靶区内。
- 3例(23%)出现≥3级不良事件,包括放射性坏死、癫痫发作和认知下降。
核心结论
- 作者认为分次放疗联合针对大体病灶的立体定向放射外科推量可达3年推量靶区内局部控制率100%且毒性可接受,可能是2级脑膜瘤有效且更优的辅助治疗策略。
研究设计与样本
- 单中心回顾性队列,纳入2009—2023年接受手术切除、分次放疗联合立体定向放射外科推量的2级脑膜瘤患者14例。
主要发现
- 10例(71.4%)在初诊时接受放射外科,4例(28.6%)因复发疾病接受治疗。
- 分次放疗中位剂量54 Gy,立体定向放射外科中位剂量7.5 Gy。
- 可随访13例中位随访34个月,3例(23%)治疗失败,均未发生在推量靶区内,其中三分之二发生在因复发疾病治疗的患者。
- 18个月无进展生存率92.3%,18个月总生存率100%。
- 多数患者无或仅有轻度不良事件,但3例(23%)出现高级别(常见不良事件评价标准v5.0 ≥3级)不良事件,包括放射性坏死、癫痫发作和认知下降。
局限性
- 单中心回顾性队列,样本量小(14例)。
- 可随访患者仅13例,中位随访34个月。
- 作者结论使用suggesting,提示该策略可能有效,尚需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Opportunity exists for improved local control rates of grade 2 meningiomas that recur despite maximal surgical resection and adjuvant fractionated radiotherapy (RT). We describe a dose escalation strategy of increasing the total tumor radiation dose by adding a stereotactic radiosurgery (SRS) boost targeting gross disease to fractionated RT. METHODS: A single-institution retrospective cohort of patients from 2009-2023 with grade 2 meningioma treated with surgical resection, fractionated RT, and SRS boost were evaluated for baseline characteristics, local disease control, and adverse events (AE). RESULTS: Fourteen meningioma patients were included. Ten patients (71.4%) underwent radiosurgery at initial diagnosis, while 4 patients (28.6%) were treated for recurrent disease. The median fractionated dose was 54 Gy, while the median dose for SRS was 7.5 Gy. Among the 13 patients with follow-up available, median follow-up was 34 months. Three patients (23%) had treatment failures; however, none occurred within the SRS volume and 2 thirds occurred in patients treated for recurrent disease. Eighteen-month progression-free survival was 92.3%, while 18-month overall survival was 100%. Most patients experienced no or mild AEs; however, 3 patients (23%) experienced a high-grade (Common Terminology Criteria for Adverse Events v5.0 grade ≥3) AE including radiation necrosis, seizures, and cognitive decline. CONCLUSIONS: We found 100% in-field local control at 3 years from an SRS boost to fractionated RT targeting gross disease with an acceptable toxicity profile, suggesting this may be an effective and improved adjuvant treatment strategy in patients with grade 2 meningioma.
引用
- Calafiore RL, Helis CA, Marcet P, et al. Fractionated Radiotherapy With Stereotactic Radiosurgery Boost Controls Gross Disease in Grade 2 Meningioma. World Neurosurg. 2024. PMID: 39579930. doi:10.1016/j.wneu.2024.11.012
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。